Luyan Pharma Co Ltd

Luyan Pharma released its 2026 interim report, with net profit attributable to the parent company of 143 million yuan, down 7.46% from the same period last year. Total operating revenue was 10.583 billion yuan, up 1.75% year on year, marking a fifth consecutive year of growth. Net cash flow from operating activities was negative 101 million yuan, down 147.98% from the same period last year. The company's latest asset-liability ratio was 74.77%, gross margin was 6.84%, return on equity was 4.32%, and diluted earnings per share was 0.37 yuan.

Luyan Pharma disclosed its 2026 interim report. In the first half, revenue rose but profit fell. Operating revenue reached 10.583 billion yuan, up 1.75% year on year. Net profit attributable to the parent company was 143 million yuan, down 7.46% year on year. Net profit after deducting non-recurring items was 138 million yuan, down 9.88% year on year. Net cash flow from operating activities was negative 101 million yuan, compared with 211 million yuan in the same period last year, a year-on-year decline of 147.98%. The company said this was mainly due to an increase in procurement payments. Pharmaceutical wholesale revenue was 9.445 billion yuan, up 0.43% year on year, accounting for 89.26% of total revenue. Pharmaceutical retail revenue was 866 million yuan, up 25.76% year on year, accounting for 8.18% of total revenue. Gross margin was 6.84% and net margin was 1.32%, both hitting new semi-annual lows since the company's listing in 2016. Accounts receivable stood at 6.187 billion yuan, accounting for 46.91% of total assets and 58.46% of current-period revenue. The share price closed at 11.68 yuan on August 17, down 44% since the start of the year.